Log In
Print
BCIQ
Print
Print this Print this
 

TLK60596

  Manage Alerts
Collapse Summary General Information
Company MabVax Therapeutics Holdings Inc.
DescriptionDual VEGFR1 and VEGFR2 kinase inhibitor
Molecular Target Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1) ; Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationColorectal cancer
Indication DetailsTreat colon cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today